Clinical Trial Update: Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab plus tremelimumab as neoadjuvant and adjuvant therapy in hepatocellular carcinoma patients undergoing percutaneous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING